To all:
Anyone interested for discussion on P-Glycoprotein (MDR1 gene) and *associated* MRP (multidrug resistance protein) inhibitors for restoring susceptibility of the cancer cells toward cytotoxic drugs.
Company of interest are: ARNX (liposomal annamycin, PI), VRTX (VX-710 and VX-853, PII), BCHE ( BCH-4556, PI), XNVAY ( XR9051, PI), ...
Several known compounds are tried in preclinical/clinical trials with mixed (mostly ambiguous) results: cyclosporin A, FK 506, probenecid, flavonoid genistein, verapamil,...
Few links for general information.
P-glycoprotein: ncbi.nlm.nih.gov
MRP: ncbi.nlm.nih.gov
ARNX: ncbi.nlm.nih.gov
VRTX: ncbi.nlm.nih.gov
BCHX: recap.com
Xenova's XR 9051: no data
Research stage: cepharanthine, apovincamicin (Japan), antisense (ISIP, Japan, Europe), monoclonal antibody UIC2 (?), MDR Agent (IMNX), ...
Connection between the MRPr1 and BLC-2 gene: ncbi.nlm.nih.gov
mz |
